

August 24, 2012

Tokyo, Japan

Micron, Inc.

PRESS RELEASE

Collaboration agreement between Micron, Inc. and Prodia DiaCRO Laboratories for the joint development of imaging clinical trial network in Southeast Asia.

Micron, Inc. (Henceforth “Micron”, Headquarters: Tokyo, Japan) and Prodia DiaCRO Laboratories (Henceforth “Prodia the CRO”, Headquarters: Indonesia) have entered into a collaboration agreement regarding international collaborative imaging trials in Southeast Asia.

Recent years in drug development have seen the wide use and increasing importance of imaging technology to accurately evaluate drug efficacy and safety in shorter period of time, compared to conventional clinical trials. In particular, this trend is clearly evident in malignant tumor and central nervous system disease studies. A great number of clinical trials use imaging technology as primary endpoints to conduct appropriate data collection and analysis. Meanwhile, globalization has sped up new drug development, thus many international collaborative clinical trials are being conducted in Asia.

Currently, there are demands for the collection and analysis of high quality international-level clinical imaging data. Therefore, imaging technology is becoming more popular. For that reason, we have created an imaging clinical trial network in Asia to meet the needs of companies from around the world. Since Prodia the CRO offers clinical trial support for drug development throughout Asia Pacific, Micron and Prodia the CRO have entered into agreement for the purpose of constructing a network for international imaging clinical trial collaboration.

As an imaging CRO, Micron is supporting the efficient drug development with PET, MRI, CT and other imaging applications in the fields of Oncology and CNS. Prodia the CRO will provide its clinical network in Indonesia, Singapore, Malaysia, and Philippine.

Prodia the CRO is a leading CRO with Headquarters in Indonesia, supporting to conduct GCP clinical trials for pharmaceuticals and biotechnology industries. Prodia

the CRO has many experiences providing services to local and multinational pharmaceuticals with high qualified and dedicated resources.

In the future, Micron will promote standardization and systematization in imaging technology under the partnership with Prodia the CRO, which will further strengthen our system of imaging clinical trials.

Outline of each company

Micron Inc.

Established: October, 2005

Headquarters: Tokyo, Japan

President and CEO: Makoto Sato

Main Services: Imaging related technical support and clinical trial support

Prodia DiaCRO Laboratories

Established: 2007

Headquarters: Jakarta Indonesia

President and CEO: Gunawan Prawira Suharto

Main Services: Clinical trial support (Indonesia, Singapore, Malaysia, Philippine),
Central laboratory service

Contact information for inquiries

Micron, Inc.

Contacts: Michita Sato, Business Development Division (for companies in Japan)

Michael Tintiuc, Director of Foreign Affairs (for companies outside of Japan)

TEL: +81-3-6268-0305

E-mail: info@micron-kobe.com

Company Website: <http://www.micron-kobe.com>